Transcript
- Slide 1
- LA NEFROPATIA A DEPOSITI MESANGIALI DI IgA University of Bari C.A.R.S.O. Consortium Valenzano, Bari F.P. Schena
- Slide 2
- ADULTS (Incidence) IgA Nephropathy 25 new cases/pmp/year Membranous glomerulopathy12 new cases/pmp/year INCIDENCE OF PRIMARY GLOMERULONEPHRITIS WORLDWIDE -Systematic review of the literature- A.McGrogan et al NDT 26, 414, 2011
- Slide 3
- The most common primary glomerulonephritis in the world: 2.5 cases/y/100,000 adults >16% in the general population: -autopsy studies (Waldherr R. et al NDT 1989) -time 0 protocol RB (Suzuki K. et al. Kidney Int 2003) Prevalence should be 250 cases/pmp in adults IgA NEPHROPATHY
- Slide 4
- High prevalence in East Asia - laws - preventive medicine Intermediate prevalence in North America and Europe - no preventive medicine - RB in patients with documented CRF (North America) Low prevalence in Africa - no preventive medicine - reduced use of immunofluorescence technique Different distribution in the world
- Slide 5
- RESEARCH GROUP ON PROGRESSIVE CHRONIC RENAL DISEASE LONG-TERM SURVIVAL OF PRIMARY GLOMERULONEPHRITIS IN JAPAN (1850 RB) Nephron 82, 205, 1999
- Slide 6
- After 5 years96% 1085% 1575% 2061% RESEARCH GROUP ON PROGRESSIVE CHRONIC RENAL DISEASE IgAN renal survival from the apparent onset of the disease or earliest known renal abnormalities in Japan Nephron 82, 205, 1999
- Slide 7
- CUMULATIVE FAILURE ESTIMATED BY KAPLAN-MEIER METHODS AS A FUNCTION OF HISTOLOGICAL CLASS IN 473 IgAN PATIENTS. THE END POINT OUTCOME IS REPRESENTED BY ESRD REQUIRING DIALYSIS OR TRANSPLANTATION C.Manno,.. and F.P.Schena et al. AJKD, 49: 763-775, 2007
- Slide 8
- T.Knoop,.. and R.Bjmeklett, AJKD, 2013 KIDNEY BIOPSY REGISTRY. KAPLAN-MEIER PLOTS OF EXPECTED VERSUS OBSERVED MORTALITY IN NORWEGIAN IgAN PATIENTS.
- Slide 9
- DEFINITION OF PATIENTS WITH FAMILIAL AND SPORADIC IgAN The relatives of at least 3 generations of each IgAN patient are checked for urinalysis Sporadic IgAN. Negative urinalysis in all relatives Familial IgAN. At least two relatives with biopsy-proven IgAN Suspectable Familial IgAN. Relatives with persistent microscopic hematuria without renal biopsy
- Slide 10
- MH 15.6% P 3% MH+P 4% 77.4% IgAN Families MH+P 0.3% P 2% MH 2% 95.7% Normal population F.P.Schena Kidney Int. 48, 1998, 1995 FREQUENCY OF URINARY ABNORMALITIES IN 269 RELATIVES FROM 48 FAMILIES OF IgAN PATIENTS AND IN 8255 STUDENTS
- Slide 11
- Mucosal infections Immunological system (innate and adaptive immunity) Abnormal production of deglycosylated IgA1 Deposition of polymeric IgA1 and IgA1-IgG immunocomplexes at glomerular level PATHOGENESIS OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN)
- Slide 12
- B cells encounter the antigen at mucosal level. Then, they migrate to the bone marrow and become the major source of aberrantly glycosylated IgA1 production HYPOTHESIS: MUCOSAL IMMUNITY AND IgAN
- Slide 13
- IgA NEPHROPATHY F.P. Schena et al. Malattie dei Reni e delle Vie Urinarie, 4 Edizione, Mc Graw-Hill, 2008
- Slide 14
- NeuAc ST6GalNAc II NeuAc ST3Gal IgA1 Ser/Thr GalNAc O GALNT2 Gal C1GALT1 +Cosmc Fab Fc Hinge region
- Slide 15
- Gharavi A.G. et al. JASN. 19: 1008-1014 2008 ABERRANT IgA1 GLYCOSYLATION IS INHERITED IN FAMILIAL IgAN
- Slide 16
- Gharavi A.G. et al. JASN. 19: 1008-1014 2008 ABERRANT IgA1 GLYCOSYLATION IS INHERITED IN RELATIVES OF SPORADIC IgAN
- Slide 17
- NeuAc ST6GalNAc II NeuAc ST3Gal IgA1 Ser/Thr GalNAc O GALNT2 Gal C1GALT1 + Cosmc Fab Fc Hinge region miR-148b let-7b
- Slide 18
- SERUM LEVELS OF COMBINED BIOMARKER (miR-148b and let-7b) G Serino,and F.P.Schena, ASN, 2012
- Slide 19
- SERUM LEVELS OF COMBINED BIOMARKER (miR-148b and let-7b) IN IgAN PATIENTS WITH NORMAL RENAL FUNCTION (NRF), DETERIORATED RENAL FUNCTION (DRF), HAEMODIALYSIS (HD) IgAN PATIENTS AND HEALTHY BLOOD DONORS G Serino,and F.P.Schena, ASN, 2012
- Slide 20
- SERUM LEVELS OF COMBINED BIOMARKER (miR-148b and let-7b) IN IgAN PATIENTS WITH MILD(G1), MODERATE (G2) AND SEVERE (G3) HISTOLOGICAL RENAL DAMAGE, AND HEALTHY BLOOD DONORS (HBD) Oxford Classification M.E.S.T. 0.0.1.0. 0.1.1.1. 1.1.1.2. G Serino,and F.P.Schena, ASN, 2012
- Slide 21
- SERUM LEVELS OF COMBINED BIOMARKER (miR-148b and let-7b) IN IgAN PATIENTS WITH HISTORY OF GROSS OR MICROSCOPIC HEMATURIA (MH), AND HEALTHY BLOOD DONORS (HBD) G Serino,and F.P.Schena, ASN, 2012
- Slide 22
- Study design
- Slide 23
- Training cohorts
- Slide 24
- Validation cohorts
- Slide 25
- Test cohorts
- Slide 26
- Effects of corticosteroid therapy on the serum levels of combined miRNA
- Slide 27
- CONCLUSIONS The combined miRNA biomarker (let-7b and miR-148b) appears to be the first robust non-invasive test for diagnosis of idiopathic IgAN without performing the renal biopsy. F.P.Schena et al (in preparation)
- Slide 28
- PREDICTION MODEL OF CANDIDATE BIOMARKERS FOR DIAGNOSIS OF IgA NEPHROPATHY (Risk scale) Serum creatinine/GFR Proteinuria Blood pressure Renal Biopsy Deglycosylated IgA1 miR148b+Let7b PreventiveProbableDefiniteProgression 1 2 3 POTENTIAL ONSET DISEASE DEVELOPMENT RENAL PROGRESSION 4
- Slide 29
- G.De Palma, G.Serino, SN.Cox, F.P.Schena, F.Sallustio, C.Curci, F.Pesce
- Slide 30